CureMatch

#PrecisionMedicine company, empowering #oncologists with personalized treatment options for patients with #cancer

[CureMatch @CureMatch]

Our #ASCO25 paper Scoring approach 1st of kind predicting #clinicaltrial outcomes:
https://t.co/A4n0QMfPrF

using #NGS +drug targeting profile, found patients who didn’t have prominent markers, YET did fairly well. For treatment planning & to qualify/quantify known+ novel drugs

[CureMatch @CureMatch]

Today we pause to remember and honor the brave men and women who made the ultimate sacrifice in service to our country. At CureMatch, we are deeply grateful for their service. Remember. Honor. Never forget.
🇺🇸
#MemorialDay #RememberAndHonor #CureMatch

[CureMatch @CureMatch]

@davidasinclair https://t.co/a9R19CKFCO

[Navid Alipour @NavidAlipour]

Despite therapeutic advances, ~50% of patients with advanced melanoma die from metastatic disease. @CureMatch helps identify actionable molecular alterations to guide personalized treatment. This is off of the #NGS lab work as our input. More at: https://t.co/563ULVzhaq

[CureMatch @CureMatch]

We couldn’t agree more @VivekSubbiah and @Papa_Heme!

[Vivek Subbiah, MD @VivekSubbiah]

Absolutely @Papa_Heme - Dr. Kurzrock is the mentor of mentors. She pushed us higher, challenged our limits, & was the one person I could always count on for bold, “out‑of‑the‑box” ideas. She’s at least ten years ahead of the field - which explains why all our ideas are out of the box @Dr_R_Kurzrock @DavidHongMD @FilipJankuMD @GarridoLagunaMD @weldeiry

[CureMatch @CureMatch]

https://t.co/rVKTxTkeu3

[CureMatch @CureMatch]

@AstraZenecaUS @PfizerOncMed @NovartisCancer @GuardantHealth @Roche

[CureMatch @CureMatch]

What we were able to show to the pharmaceutical world, is not something that had been done before: our score was highly significant in predicting patients’ response to a novel FGFR inhibitor based on molecular data we analyzed while blinded to the outcomes of the clinical trial.

[CureMatch @CureMatch]

Our #ASCO25 paper Scoring approach 1st of kind predicting #clinicaltrial outcomes:
https://t.co/A4n0QMfPrF

using #NGS +drug targeting profile, found patients who didn’t have prominent markers, YET did fairly well. For treatment planning & to qualify/quantify known+ novel drugs

[CureMatch @CureMatch]

🌸 Happy Mother’s Day 🌸
Today, we honor the incredible mothers, grandmothers, daughters, sisters, and mother figures who fill our lives with strength, love, and resilience.
At #CureMatch, we are committed to supporting women and their families through #precisiononcology.

[Navid Alipour @NavidAlipour]

A great visual of what @CureMatch does:

[CureMatch @CureMatch]

We have GBM patient we assisted, 5-6 years out in remission! Definition of insanity is doing the same thing expecting different results.

[CureMatch @CureMatch]

@LoriMills4CA42 DM us please. If you have done next gen sequencing from any of the labs like @GuardantHealth @TempusAI @CARISLab @NeoGenomics their lab output is our input.

[CureMatch @CureMatch]

@DrMakaryFDA We are excited to participate!

[CureMatch @CureMatch]

@DrMakaryFDA We can help. Look at our #ASCO abstract from 2025. No other company has achieved these results.

[CureMatch @CureMatch]

@DrMakaryFDA We can help. Look at our #ASCO abstract from 2025. No other company has achieved these results.

[CureMatch @CureMatch]

By leveraging comprehensive next-gen sequencing & multiomic profiling, tumors can be analyzed in greater depth. Enabling IDing of actionable biomarkers & selection of personalized therapies

[CureMatch @CureMatch]

#Precisiononcology tailors treatment to the molecular profile of patient’s tumor. Traditional therapies rely on histological classification & the tumor’s site of origin, often failing to account for tumor heterogeneity.

[CureMatch @CureMatch]

Precision-oncology is critical with all #cancers, with Pancreatic cancer at the top of the list. Next gen sequencing of the biopsy, is the input we need to then provide our clinical decision support.

[CureMatch @CureMatch]

We have GBM patient we assisted, 5-6 years out in remission! Definition of insanity is doing the same thing expecting different results.

[Razelle Kurzrock, MD @Dr_R_Kurzrock]

An amazing editorial. Stupp says it’s time to move beyond Stupp. I agree. For GBM, every patient needs a clinical trial in front line. Stupp moved the field 20 years ago, but now we need more; oncology is being transformed; GBM should not continue to be left behind

[CureMatch @CureMatch]

Molecular Tumor Boards serve a great role as to treatment recommendations. #PrecisionOncology based on specific tumor molecular alterations, has voluminous multi-omic data. Millions of combos, each cancer 5 mutations on average, a trillion patterns! We can help. @Dr_R_Kurzrock

[CureMatch @CureMatch]

🌟 Thrilled to be at #AACR2026!
@CureMatch, we’re advancing precision #oncology by turning #genomic insights into ranked, actionable treatment options that help #oncologists match patients with the best possible combination therapies. @Dr_R_Kurzrock